Search
Search Results
##search.searchResults.foundPlural##
-
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1509PDF: 933Suppl. Files: 464HTML: 291 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
5038PDF: 1340HTML: 1927Untitled: 194Untitled: 190 -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
2066PDF: 955HTML: 1774Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 182 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2237PDF: 1762HTML: 821 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3729PDF: 920HTML: 6859 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
1010PDF: 1240HTML: 118 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
974PDF: 535HTML: 217 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1924PDF: 1191HTML: 331 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2639PDF: 822HTML: 5357 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1704PDF: 532HTML: 342 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1127PDF: 568Suppl. Files: 135HTML: 399 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3880PDF: 1704HTML: 11779Figures Haase: 224 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1428PDF: 1660Suppl. Files: 172HTML: 87 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1774PDF: 1221HTML: 312 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4433PDF: 1791HTML: 1112 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1224PDF: 782HTML: 1527Figure 1: 209Figure 2: 205 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
539PDF: 269HTML: 104 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1817PDF: 583HTML: 354 -
ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
1725PDF: 838HTML: 962cover letter: 288 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2782PDF: 1151HTML: 7740cover letter paper final AML: 235 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9248PDF: 6156HTML: 88023Fig.1b: 202Fig.1c: 210Fig.2a: 198Fig.2b: 194Fig.4: 216Fig.2c: 197Fig.3: 200Tab.1: 250Tab.2: 227Tab.3: 210Tab.4: 244Fig1a: 206 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1313PDF: 1059HTML: 399 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3576PDF: 911HTML: 1671figure 1: 178Untitled: 204 -
Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission
1733PDF: 805HTML: 295 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2599PDF: 867HTML: 9051Efremov 1: 248Efremov 2: 211 -
RECENT ADVANCES IN THE 5Q- SYNDROME
2876PDF: 1856HTML: 3756Pellagatti Fig 1: 233Pellagatti Fig. 2: 230 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1440HTML: 625PDF: 862 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1318PDF: 793HTML: 351 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1534PDF: 813Suppl. Files: 340Html: 141







